Table 1

Baseline demographics, clinical characteristics and treatment utilisation based on HLA-B*27 status

Total
N=2269
HLA-B*27 +
N=1753
HLA-B*27 –
N=516
P value
Age41.3 (12.8)40.6 (12.8)43.4 (12.6)<0.001
Gender (male)1554 (68.0%)1264 (72.1%)280 (54.3%)<0.001
University studies1056/2267 (46.6%)837/1751 (47.8%)219 (42.4%)0.032
Family history of axSpA601 (26.5%)522 (29.8%)79 (15.3%)<0.001
Age of symptoms onset26.8 (10.0)25.9 (9.4)30.0 (11.1)<0.001
Age of diagnosis33.0 (11.5)31.6 (10.9)37.7 (12.1)<0.001
BMI25.9 (5.1)25.7 (4.9)26.5 (5.6)0.001
Past or current peripheral arthritis981/2266 (43.3%)736/1750 (42.1%)245 (47.5%)0.029
Past or current enthesitis1165/2268 (51.4%)873/1752 (49.8%)292 (56.6%)0.007
Past or current dactylitis205 (9.0%)153 (8.7%)52 (10.1%)0.347
Past or current uveitis520 (22.9%)461 (26.3%)59 (11.4%)<0.001
Past or current psoriasis279/2268 (12.3%)179/1752 (10.2%)100 (19.4%)<0.001
Past or current IBD125 (5.5%)59 (3.4%)66 (12.8%)<0.001
NSAIDs ever1606 (70.8%)1240 (70.7%)366 (70.9%)0.932
csDMARDs ever1281 (56.5%)965 (55.0%)316 (61.2%)0.013
bDMARDs ever1377 (60.7%)1070 (61.0%)307 (59.5%)0.529
  • axSpA, axial spondyloarthritis; bDMARDs, biological disease-modifying anti-rheumatic drugs; BMI, body mass index; csDMARDs, conventional synthetic disease-modifying anti-rheumatic drugs; JuvSpA, juveline spondyloarthritis; PsA, psoriatic arthritis; pSpA, peripheral spondyloarthritis; REA, reactive arthritis.